(Q38221980)

31 August 2017

Clinical implication of SGLT2 inhibitors in type 2 diabetes (English)

1 reference

31 August 2017

1 reference

Go Woon Kim

1

1 reference

31 August 2017

Sung Hyun Chung

series ordinal

2

1 reference

31 August 2017

21 June 2014

1 reference

Archives of Pharmacal Research

31 August 2017

1 reference

31 August 2017

37

1 reference

31 August 2017

8

1 reference

31 August 2017

957-966

1 reference

https://scigraph.springernature.com/pub.10.1007/s12272-014-0419-0

31 August 2017

0 references

cites work

Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Pancreatic alpha-cell dysfunction in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Current strategies for the inhibition of hepatic glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Compound K enhances insulin secretion with beneficial metabolic effects in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Mechanisms linking obesity to insulin resistance and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Glucose control by the kidney: an emerging target in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Ipragliflozin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Type 2 diabetes: principles of pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

The SLC2 family of facilitated hexose and polyol transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Biology of human sodium glucose transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

Luseogliflozin: First Global Approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-014-0419-0

10.1007/S12272-014-0419-0

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1048225579

0 references

Fatcat ID

release_nkvto4nycnfwbclbo6cix2xu5m

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nkvto4nycnfwbclbo6cix2xu5m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference